Search
SOLACI Congress
HomePeripheral vascular diseaseInfrapatellar

Infrapatellar

View Category

Antithrombotic Anticoagulants

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of...
solaci -
Learn More
Antithrombotic Anticoagulants

Virtual ACC 2020 | COMPASS Sub-Analysis: Diabetes Increases the Benefit of Rivaroxaban Combined with AAS

In patients with stable coronary or peripheral artery disease, diabetes increases the benefit of combining low doses...
solaci -
Learn More
Infrapatellar

Drug-Coated Balloons in Infrapopliteal Disease: Much Ado About Nothing

The revascularization of tibial arteries in patients with critical lower limb ischemia using drug-coated balloons vs. conventional...
solaci -
Learn More
Aorta

New European Guidelines on the Management of Lower Limb Acute Ischemia

Clinical practice guidelines are usually tedious and, frankly, while a lot of people make an enormous effort...
solaci -
Learn More
Infrapatellar

Drug-Coated Balloons vs. Conventional Angioplasty Below the Knee

This meta-analysis is an update on the role of drug-coated balloons in the treatment of infrapopliteal arterial...
solaci -
Learn More
Antiplatelet

We Should Indicate More than 6 Months of DAPT in Lower Limb Disease

Courtesy of Dr. Carlos Fava. Advanced peripheral vascular disease is frequently associated with cardiovascular events and amputation. It has...
solaci -
Learn More
Femoropopliteal

Improved Outcomes after Lower Limb Revascularization

Operator ability combined with improved and diverse devices for lower limb revascularization has clearly increased in the...
solaci -
Learn More
Infrapatellar

The Importance of Tibial Artery Patency in the Rechanneling of the Femoral Artery

After rechanneling occluded superficial femoro-popliteal arteries, interventional physicians are left with the question of how to proceed...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

AHA 2024 | VANISH2 Trial

Dr. Omar Tupayachi - 0
Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

Dr. Omar Tupayachi - 0
It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Dr. Omar Tupayachi - 0
Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Institutional News

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy